Pacira BioSciences, Inc. PCRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $177.38M-9.9% | $196.87M+9.7% | $179.52M-0.9% | $181.1M+7.2% | $168.92M-9.8% | ||
| $36.41M-9.6% | $40.3M+17.6% | $34.28M-16.1% | $40.87M+19.1% | $34.31M-14.0% | ||
| $140.96M-10.0% | $156.57M+7.8% | $145.24M+3.6% | $140.23M+4.2% | $134.62M-8.7% | ||
| 79.5%-0.1pp | 79.5%-1.4pp | 80.9%+3.5pp | 77.4%-2.3pp | 79.7%+1.0pp | ||
| $28.07M-25.0% | $37.45M+44.2% | $25.97M-7.9% | $28.2M+11.3% | $25.34M+6.0% | ||
| $93.94M-7.5% | $101.61M+10.7% | $91.8M+3.6% | $88.58M+2.1% | $86.78M+9.0% | ||
| $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | ||
| $2.28M— | —— | —— | —— | -$6.19M— | ||
| $170.47M-12.4% | $194.53M+12.3% | $173.15M+0.3% | $172.6M+3.4% | $166.93M+2.7% | ||
| $6.9M+195% | $2.34M-63.2% | $6.36M-25.1% | $8.5M+327% | $1.99M— | ||
| 3.9%+2.7pp | 1.2%-2.4pp | 3.5%-1.1pp | 4.7%+3.5pp | 1.2%— | ||
| $3.7M-5.0% | $3.89M-9.0% | $4.28M-8.9% | $4.7M+2.5% | $4.58M-2.1% | ||
| $1.93M-15.9% | $2.3M-73.1% | $8.53M+70.4% | $5.01M-27.4% | $6.9M+24.1% | ||
| -$1.9M-7.6% | -$1.77M-156% | $3.16M+130% | -$10.43M-255% | $6.72M+717% | ||
| $5M+775% | $571K-94.0% | $9.52M+594% | -$1.93M-122% | $8.71M— | ||
| $2.08M— | —— | $4.09M+40.1% | $2.92M-25.0% | $3.89M-58.9% | ||
| $2.92M+78.1% | $1.64M-69.9% | $5.43M+212% | -$4.85M-201% | $4.81M— | ||
| 1.6%+0.8pp | 0.8%-2.2pp | 3%+5.7pp | -2.7%-5.5pp | 2.8%— | ||
| $0.07+75.0% | $0.04-66.7% | $0.12+209% | -$0.11-210% | $0.10— | ||
| $0.07+75.0% | $0.04-66.7% | $0.12+209% | -$0.11-210% | $0.10— | ||
| 40.9M-9.2% | 45M+1.3% | 44.5M-2.2% | 45.5M-2.3% | 46.5M+0.6% | ||
| 40.5M-9.2% | 44.6M+1.2% | 44M-3.1% | 45.5M-1.8% | 46.3M+0.1% | ||
| $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | $14.32M0.0% | ||
| -$135K+21.5% | -$172K-56.4% | -$110K+99.0% | -$10.74M-344% | $4.4M+8,404% | ||
| $2.28M— | —— | —— | —— | -$6.19M— | ||
| $177.38M-9.9% | $196.87M+9.7% | $179.52M-0.9% | $181.1M+7.2% | $168.92M-9.8% | ||
| $6.9M+195% | $2.34M-63.2% | $6.36M-25.1% | $8.5M+327% | $1.99M— | ||
| $28.23M+19.2% | $23.68M-14.0% | $27.55M-23.1% | $35.82M+54.7% | $23.16M— | ||
| $28.23M+19.2% | $23.68M-14.0% | $27.55M-23.1% | $35.82M+54.7% | $23.16M— | ||
| 15.9%+3.9pp | 12%-3.3pp | 15.3%-4.4pp | 19.8%+6.1pp | 13.7%— | ||
| $6.9M+195% | $2.34M-63.2% | $6.36M-25.1% | $8.5M+327% | $1.99M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacira BioSciences, Inc.'s revenue?
- Pacira BioSciences, Inc. (PCRX) generated $734.9M in revenue over the trailing twelve months, up 4.6% year over year.
- Is Pacira BioSciences, Inc. profitable?
- Pacira BioSciences, Inc. reported $5.1M in net income over the trailing twelve months, a 0.7% net margin.
- What are Pacira BioSciences, Inc.'s profit margins?
- Gross margin is 79.3% and operating margin is 3.3%, with a 0.7% net margin.
- What is Pacira BioSciences, Inc.'s earnings per share?
- Pacira BioSciences, Inc.'s diluted EPS over the trailing twelve months is $0.12.
- Where does Pacira BioSciences, Inc.'s income statement data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
